Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
"The new year holds a great deal of promise for the field of regenerative medicine, with companies like NEO at the forefront." (12/30/14) NeoStem Inc. - The Life Sciences Report Interview with Steve Brozak Moreá>
Raghuram "Ram" Selvaraju's professional career started at the Geneva-based biotech firm Serono in 2000, where he discovered the first novel protein candidate developed entirely within the company. He subsequently became the youngest recipient of the company's Inventorship Award for Exceptional Innovation and Creativity. Selvaraju started in the securities industry with Rodman & Renshaw as a biotechnology equity research analyst. He was the top-ranked (#1) biotech analyst in The Wall Street Journal's "Best on the Street" survey (2006) and went on to become head of healthcare equity research at Hapoalim Securities, the New York-based broker/dealer subsidiary of Bank Hapoalim B. M., Israel's largest financial services group. While at Hapoalim, Selvaraju was regularly featured in The Wall Street Journal, Barron's, BioWorld Today, and Reuters/AP. He was also a regular guest on the Bloomberg TV program "Taking Stock," appeared with Bloomberg TV's on-air correspondents Betty Liu and Gigi Stone and was a guest on CNBC's "Street Signs with Herb Greenberg."
Bring On the Orphans: Aegis Capital's Raghuram Selvaraju Lays Out a Winning Biotech Strategy (8/14/14) For former drug researcher Raghuram "Ram" Selvaraju, picking biotech stocks is both science and art. It's about understanding the competitive landscape and the mechanisms of drug action, and then making sure all the pieces fit together for a plausible investment case. In this interview with The Life Sciences Report, the managing director and head of healthcare equity research at Aegis Capital lays out his growth hypothesis for companiesŚseveral targeting orphan diseasesŚthat he believes will nurture portfolios.
Do the Math: Ram Selvaraju on the Appeal of Biotechs in Orphan Diseases (4/22/14) To cast a spotlight on disruptive biotechnology stocks, Raghuram "Ram" Selvaraju of Aegis Capital Corp. taps his experience as a molecular biologist, preclinical investigator and sellside analyst. In this, the last of his three interviews with The Life Sciences Report, Selvaraju highlights micro-, small- and mid-cap biotech names with therapies that may add years to patients' lives and liftoff to investor portfolios.
Ram Selvaraju: A Pair of Companies Ride the Sea Change in Cancer Therapeutics (2/4/14) A new generation of oncology treatments is moving through clinical trials toward the market. These proposed products are revolutionary in both their approaches to disease and their expected efficacy. Raghuram "Ram" Selvaraju, armed with his background as a drug developer, has followed dozens of highly innovative small- and mid-cap biotech companies, many of which he originally spotted as micro caps. In his second of three interviews with The Life Sciences Report, the head of equity healthcare research at Aegis Capital Corp. highlights two names with huge growth prospects.
"If the data from the PRESERVE trial are positive, NEO may be able to enter partnership in the regenerative medicine space." (4/22/14) NeoStem Inc. - The Life Sciences Report Interview with Raghuram Selvaraju Moreá>
"We think that CGXI is an attractive investment at this juncture primarily because it has a diversified revenue model." (12/5/13) Cancer Genetics Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"We have raised our 12-month price target for CPRX to $6/share; the profile for CPP-115 keeps getting better and better." (11/25/13) Catalyst Pharmaceutical Partners Inc. - Ram Selvaraju, Aegis Capital Moreá>
"Firdapse could generate $80ľ100M in sales every year for CPRX, which has a $40M market cap." (7/18/13) Catalyst Pharmaceutical Partners Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"We continue to be positive on GALE's NeuVax, which is proposed to prevent recurrence of breast cancer in disease-free patients." (7/18/13) Galena Biopharma Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"CUR is one of the best stories in the stem cell arena and it has a rich calendar of catalysts in 2013 and into H1/14." (7/18/13) Neuralstem Inc. - The Life Sciences Report Interview with Ram Selvaraju Moreá>
"Animal data has indicated LPTN's ASONEP™ may have activity in renal cell carcinoma, including that which is resistant to currently marketed drugs." (3/14/13) Lpath Inc. - Ram Selvaraju, Aegis Capital Moreá>
"If all goes well, CUR's NSI-189 product will move into Phase 2 development in Q2/15, so that is a good advancement opportunity." (1/22/15) Neuralstem Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>
"ATHX completed enrollment in its Phase 2 stroke study before the new year, so the first 90-day results will emerge in Q1/15E." (1/22/15) Athersys Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>
"The research synergy with Gilead and Merck could prove fruitful for RNN in terms of acquisition potential." (1/22/15) Rexahn Pharmaceuticals Inc. - The Life Sciences Report Interview with Edward Stopke Moreá>